Nasdaq:APRE
Aprea Therapeutics, Inc.
A pre-revenue biotech firm targeting severe inflammatory bowel diseases using a proprietary small molecule platform to disrupt the crowded biologics space.
Key Metrics
Investment Thesis
Bull Case
If Aprea successfully completes its pivotal trials, investors could see significant value appreciation as the company transitions from clinical-stage to commercialization in the lucrative IBD market. The proprietary small molecule platform offers a differentiated profile against expensive biologics, potentially providing a first-mover advantage in oral therapy segments. Early entry into partnerships or licensing deals could unlock substantial non-dilutive cash inflows to extend the runway.
Bear Case
The stock carries extreme binary risk as the company has no current revenue and a massive retained earnings deficit of over $300M that must be resolved through future financing or successful sales. Investors face the likelihood of further dilution as cash reserves dwindle, which could erode shareholder value even if clinical milestones are met. The lack of established product revenue makes it impossible to calculate meaningful valuation multiples based on traditional financial metrics.
About Aprea Therapeutics, Inc.
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for severe inflammatory diseases such as Crohn's disease and ulcerative colitis. The company leverages its proprietary technology platform to identify and advance targeted treatments within the competitive biologics market. With minimal current revenue, the firm relies entirely on capital markets to fund its extensive clinical trial programs and R&D initiatives.
Analysis
Management Discussion
The company reported a net loss of $13.0M in 2024, reflecting continued heavy investment in R&D and general administrative expenses totaling $6.5M. Despite generating positive cash flow from financing activities of $14.8M via share issuances, operating cash flow remained negative at -$13.6M, indicating the company is burning through its cash reserves to sustain clinical trial operations. Total assets stood at $24.0M with a retained earnings deficit of -$321.0M, highlighting the historical capital requirements needed to advance its pipeline.
Industry Overview
The biopharmaceutical industry for inflammatory bowel disease is dominated by large pharmaceutical companies offering expensive monoclonal antibody therapies that face increasing payer pressure. Emerging small molecule competitors aim to provide more convenient oral alternatives, creating a shifting competitive landscape where first-in-class or best-in-class assets command premium valuations. Regulatory pathways for new mechanisms of action remain rigorous, requiring substantial investment before any commercial return can be realized.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | $-583.2K | $-1.5M |
| Gross Profit | $583.2K | $1.5M |
| Operating Expenses | $16.1M | $15.8M |
| Operating Income | $-15.5M | $-14.3M |
| G&A | $8.4M | $6.5M |
| D&A | $7.1K | $22.3K |
| Other OpEx | $7.6M | $9.4M |
| Non-Operating Income | $0 | $0 |
| Pre-Tax Income | $-15.5M | $-14.3M |
| Income Tax | $0 | $0 |
| Continuing Ops | $-15.5M | $-14.3M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-14.3M | $-13.0M |
| Minority Interest | $0 | $0 |
| Net to Common | $-14.3M | $-13.0M |
| Metric | 2023 | 2024 |
|---|---|---|
| Current Assets | $22.5M | $23.6M |
| Cash & Equivalents | $21.6M | $22.8M |
| Prepaid Expenses | $914.3K | $726.3K |
| Other Current Assets | $0 | $0 |
| Long-Term Assets | $129.1K | $403.4K |
| PP&E (Net) | $88.4K | $81.5K |
| Other LT Assets | $40.7K | $321.8K |
| Total Assets | $22.7M | $24.0M |
| Current Liabilities | $4.4M | $3.4M |
| Accounts Payable | $1.7M | $1.4M |
| Other Current Liab | $2.7M | $2.0M |
| Long-Term Liabilities | $1.3M | $1.3M |
| Total Liabilities | $5.7M | $4.7M |
| Shareholders' Equity | $17.0M | $19.3M |
| Paid-In Capital | $335.6M | $351.0M |
| Retained Earnings | $-308.1M | $-321.0M |
| AOCI | $-10.6M | $-10.6M |
| Total L&E | $22.7M | $24.0M |
| Metric | 2023 | 2024 |
|---|---|---|
| Net Income (CFO) | $-14.3M | $-13.0M |
| Non-Cash Adjustments | $1.4M | $264.0K |
| Working Capital Changes | $714.7K | $-862.0K |
| Cash from Operations | $-12.2M | $-13.6M |
| Capital Expenditures | $93.1K | $15.5K |
| Cash from Investing | $-93.1K | $-15.5K |
| Cash from Financing | $5.1M | $14.8M |
| FX Effect | $-8.4K | $-7.2K |
| Net Change in Cash | $-7.1M | $1.2M |
| Beginning Cash | $28.8M | $21.6M |
| Ending Cash | $21.6M | $22.9M |
Frequently Asked Questions
How does Aprea Therapeutics, Inc. make money?
The company operates primarily through its core therapeutic development segment, focusing on Apremilast-based oral therapies for autoimmune conditions. Due to the clinical-stage nature of the business, revenue is currently generated solely from research grants or strategic partnerships rather than commercial product sales. All financial resources are directed toward high-risk, high-reward late-stage asset development programs.
What are the main risks for APRE?
As a clinical-stage company with no commercial revenue, the business faces extreme vulnerability to dilution from equity issuances to fund ongoing operations. The high probability of trial failure or regulatory rejection for its pipeline assets poses an existential threat to the company's valuation and longevity. Significant competition from established biologics giants could limit future market share even if clinical success is achieved. Cash reserves are depleting rapidly, and the company requires continuous access to capital markets to survive.
What is APRE's competitive advantage?
The firm possesses a unique proprietary technology platform capable of identifying and optimizing small molecule drugs to target specific inflammatory pathways. Aprea benefits from an experienced management team with deep expertise in translational medicine and successful track records in advancing assets through clinical trials. The company maintains strategic partnerships and licensing agreements that provide upfront capital and potential milestone payments, reducing immediate cash burn pressure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.